Meda AB Acquires Exclusive Rights to New Treatment of Actinic Keratosis From Graceway Pharmaceuticals, LLC

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product has recently been approved in the US and Canada.

Back to news